<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2011234516
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Allocar
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FINASTERIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        68.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; III" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – III
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        QD11AX10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Allocar contains a medicine called Finasteride. This belongs to a group of medicines called &lsquo;5alpha reductase inhibitors.</p><p>Allocar shrinks the prostate gland in men when it is swollen. The prostate gland is found underneath the bladder (but only in men). It produces the fluid found in semen. A swollen prostate gland can lead to a condition called &lsquo;benign prostatic hyperplasia&rsquo; or BPH.</p><p><strong>What is BPH? </strong></p><p>If you have BPH it means that your prostate gland is swollen. It can press on the tube that urine passes through, on its way out of your body.</p><p>This can lead to problems such as:</p><p>&bull;&nbsp;&nbsp;&nbsp; feeling like you need to pass urine more often, especially at night.</p><p>&bull;&nbsp;&nbsp;&nbsp; feeling that you must pass urine right away.</p><p>&bull;&nbsp;&nbsp;&nbsp; finding it difficult to start passing urine.</p><p>&bull;&nbsp;&nbsp;&nbsp; when you pass urine the flow of urine is weak</p><p>&bull;&nbsp;&nbsp;&nbsp; when you pass urine, the flow stops and starts.</p><p>&bull;&nbsp;&nbsp;&nbsp; feeling that you cannot empty your bladder completely in some men, BPH can lead to more serious problems, such as:</p><p>&bull;&nbsp;&nbsp;&nbsp; urinary tract infections</p><p>&bull;&nbsp;&nbsp;&nbsp; a sudden inability to pass urine</p><p>&bull;&nbsp;&nbsp;&nbsp; the need for surgery</p><p><strong>What else should you know about BPH? </strong></p><p>&bull;&nbsp;&nbsp;&nbsp; BPH is not cancer and does not lead to cancer, but the two conditions can be present at the same time.</p><p>&bull;&nbsp;&nbsp;&nbsp; Before you start Allocar, your doctor will do some simple tests to check whether you have prostate cancer.</p><p>Talk to your doctor if you have any questions about this</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are a woman (because this medicine is for men)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic (hypersensitive) to finasteride or any of the other ingredients of this medicine (listed in Section 6).</p><p>Do not take Allocar if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist.</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Allocar if:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your partner is pregnant or planning to become pregnant. You should use a condom or other barrier method of contraception when taking Allocar. This is because your semen could contain a tiny amount of the drug and may affect the normal development of the baby&rsquo;s sex organs.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are going to have a blood test called PSA. This is because Allocar can affect the results of this test.</p><p>If you are not sure, talk to your doctor or pharmacist before taking Allocar.</p><p>Mood alterations and depression</p><p>Mood alterations such as depressed mood, depression and, less frequently, suicidal thoughts have been reported in patients treated with Allocar. If you experience any of these symptoms contact your doctor for further medical advice as soon as possible.</p><p><strong>Children </strong></p><p>Allocar should not be used in children.</p><p>Taking other medicines</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Allocar does not usually affect other medicines.</p><p><strong>Taking Allocar with food and drink </strong></p><p>Allocar can be taken with or without food.</p><p>Pregnancy and breast feeding</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Allocar should not be taken by women.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Do not touch crushed or broken Allocar tablets if you are a woman who is pregnant or planning to become pregnant (whole tablets are coated to stop contact with the medicine during normal use). This is because this medicine may affect the normal development of the baby&rsquo;s sex organs.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; If a woman who is pregnant comes into contact with crushed or broken Allocar tablets, speak to your doctor.</p><p><strong>Driving and using machines </strong></p><p>Allocar is not likely to affect you being able to drive, use tools or machines.</p><p>Allocar contains</p><p>Lactose. This is a type of sugar. If you have ever been told by your doctor that you cannot tolerate or digest some sugars (have an intolerance to some sugars), talk to your doctor or pharmacist before taking this medicine.</p><p>Allocar contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Taking this medicine</p><p>&bull;&nbsp;&nbsp;&nbsp; The usual dose is one tablet each day.</p><p>&bull;&nbsp;&nbsp;&nbsp; Take this medicine by mouth.</p><p>&bull;&nbsp;&nbsp;&nbsp; Your doctor may prescribe Allocar along with another medicine (called doxazosin) to help control your BPH.</p><p><strong>If you take more Allocar than you should </strong></p><p>If you take too many tablets by mistake, contact your doctor immediately.</p><p>If you forget to take Allocar</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget to take a tablet, skip the missed dose.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take the next dose as usual.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten dose.</p><p>If you stop taking Allocar</p><p>Your condition may show an early improvement after taking Allocar. However, it may take at least six months for the full effect to develop. It is important to keep taking Allocar for as long as your doctor tells you, even if you do not feel any benefit straight away.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p>Allergic reactions</p><p>Stop using Allocar and immediately contact a doctor if you experience any of the following symptoms:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of face, lips, tongue or throat, difficulty swallowing and breathing difficulties</p><p>(angioedema)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rashes, itching, or lumps under your skin (hives).</p><p><strong>Other side effects may include: </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may be unable to have an erection (impotence)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may have less desire to have sex.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may have problems with ejaculation, for example a decrease in the amount of semen released during sex. This decrease in the amount of semen does not appear to affect normal sexual function.</p><p>These side effects above may disappear after a while if you continue taking Allocar. If not, they usually resolve after stopping Allocar. Other side effects reported in some men are:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast swelling or tenderness.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palpitations (feeling your heartbeat)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in the way your liver is working, which can be shown by a blood test.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in your testicles</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood in semen</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An inability to have an erection which may continue after stopping the medication.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Male infertility and/or poor quality of semen. Improvement in the quality of the semen has been reported after stopping medication.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in sex drive that may continue after stopping the medication.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with ejaculation that may continue after stopping the medication.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety</p><p>You should promptly report to your doctor any changes in your breast tissue such as lumps, pain, enlargement or nipple discharge as these may be signs of a serious condition, such as breast cancer. If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. It will help if you make a note of what happened, when it started and how long it lasted.</p><p><strong>What else should you know about Allocar? </strong></p><p>Allocar (finasteride) is not licensed to treat prostate cancer. Information collected for a clinical trial in men taking finasteride for 7 years showed:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The number of men who developed prostate cancer was lower in men taking finasteride compared with those taking nothing.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The number of men who had a high score in a tumour grading system was higher in some of those taking finasteride compared to those taking nothing.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The effect of long-term use of finasteride on tumours of this kind is not known.</p><p>If you would like further information about the tumour grading system or this trial, please talk to your doctor</p><p>Reporting of side effect</p><p>&bull; If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from moisture.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Finasteride.</p><p>Each film coated tablet contains Finasteride Ph.Eur 5 mg.</p><p><strong>The other ingredients are </strong>cellulose microcrystalline, Lactose monohydrate, starch pregelatinized Sodium starch glycolate, Docusate sodium, Magnesium stearate.</p><p><strong>Film Coating Composition: </strong>HPMC 2910/Hypromellose 6cP, Titanium Dioxide, FD&amp;C Blue #2/Indigo Carmine Aluminum Lake, Talc, Iron Oxide Yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Blue colour, round film coated tablets, debossed with 'H' on one side and '37' on other side.

How supplied:

Finasteride Tablets 5 mg are supplied in Blister pack.

Allocar – contains Box of 30 blister tablets (3 x 10’s) Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder and Manufacturer Saudi Amarox Industrial Company</p><p>Aljameah Street, Malaz quarter,</p><p>Riyadh 12629, Saudi Arabia</p><p>Tel: +966 11 226 8850</p><p>Manufacturer</p><p>Hetero Lab Limited Unit III, Telangana, India</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                    Last revised in October 2023, Version 1 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">یحتوي ألوكار على مادة فعالة تسمى فیناستراید. ینتمي فیناستراید إلى مجموعة من الأدویة تسمى &quot;مثبطات اختزال ٥-ألفا&quot; النوع الثاني .&nbsp;</p><p dir="RTL">یعمل ألوكار أقراص على انكماش غدة البروستاتا عند الرجال وذلك عندما تكون متورمة .توجد غدة البروستاتا تحت المثانة (ولكن فقط عند الرجال.) حیث تتمثل وظیفتھا في انتاج السائل الموجود في السائل المنوي. یمكن أن تؤدي غدة البروستاتا المنتفخة إلى حالة تسمى &quot;تضخم البروستاتا الحمید&quot; أو BPH .</p><p dir="RTL"><strong>ما ھو تضخم البروستاتا الحمید؟ </strong></p><p dir="RTL">إذا كنت مصاباً بتضخم البروستاتا الحمید ، فھذا یعني أن غدة البروستاتا متورمة .ویم كن أن یقوم ھذا التورم بالضغط على الأنبوب الذي یمر من خلالھ البول ، في طریقھ للخروج من جسمك.&nbsp;</p><p dir="RTL">ھذا یمكن أن یؤدي إلى مشاكل مثل:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالحاجة إلى التبول أكثر من مرة ، خاصة في اللیل .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بضرورة التبول على الفور .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجد صعوبة في التبول.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند التبول یكون تدفق البول ضعیفا ً.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند التبول یتوقف التدفق ویبدأ.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بعدم قدرتك على إفراغ مثانتك بالكامل .</p><p dir="RTL">یمكن أن یؤدي تضخم البروستاتا الحمید إلى مشاكل أكثر خطورة في بعض الرجال ، مثل:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھابات المسالك البولیة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور المفاجئ&nbsp; بعدم القدرة على التبول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحاجة إلى اجراء جراحة .</p><p dir="RTL"><strong>ما الذي یجب أن تعرفھ أیضًا عن تضخم البروستاتا الحمید؟ </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا یعتبر تضخم البروستاتا الحمید سرطاناً ولا یؤدي إلى الإصابة بالسرطان ، ولكن یمكن أن تكون الحالتان موجودتان في نفس الوقت الوقت .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل أن تبدأ بالعلاج بتناول ألوكار ، سیقوم طبیبك بإجراء بعض الاختبارات البسیطة للتحقق مما إذا كنت مصاباً بسرطان البروستاتا.</p><p dir="RTL">تحدث إلى طبیبك إذا كان لدیك أي أسئلة حول ھذا الموضوع.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أقراص&nbsp; </strong>یجب عدم تناول ألوكار أقراص في الحالات التالیة:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت امرأة (لأن ھذا الدواء للرجال)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسیة (الحساسیة الشدیدة) لمادة فیناستراید أو أي من المكونات الأخرى لھذا الدواء (المدرجة في القسم ٦) .</p><p dir="RTL">یجب عدم تناول ألوكار إذا كان أي مما سبق ینطبق علیك. وإذا لم تكن متأكًدًا ، تحدث إلى طبیبك أو الصیدلي.</p><p dir="RTL"><strong>التحذیرات والإحتیاطات </strong></p><p dir="RTL">تحدث إلى طبیبك أو الصیدلي قبل تناول ألوكار في االحالات التالیة :</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت شریكتك حامل أو تخطط للحمل. یجب علیك استخدام الواقي الذكري أو أي وسیلة أخرى لمنع الحمل عند تناول ألوكار. وذلك لأن السائل المنوي الخاص بك یمكن أن یحتوي على كمیة ضئیلة من الدواء وقد یؤثر على النمو الطبیعي للأعضاء التناسلیة لدى الطفل.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستخضع لفحص دم لسرطان البروستاتا یسمى PSA (مستضد البروستاتا النوعي). ھذا لأن ألوكار یمكن أن یؤثر على نتیجة ھذا الاختبار.</p><p dir="RTL">إذا لم تكن متأكًدًا ، تحدث إلى طبیبك أو الصیدلي قبل تناول ألوكار.</p><p dir="RTL"><strong>التغیرات المزاجیة والاكتئاب&nbsp; </strong></p><p dir="RTL">تم الإبلاغ عن تغیرات في الحالة المزاجیة مثل المزاج المكتئب والاكتئاب ، والأفكار الانتحاریة (بمعدلات منخفضة) وذلك في المرضى الذین عولجوا بـاستخدام ألوكار. إذا واجھت أیًا من ھذه الأعراض ، فتوقف عن تناول ألوكار واتصل بطبیبك للحصول على مزید من النصائح الطبیة في أقرب وقت ممكن.&nbsp;</p><p dir="RTL"><strong>الأطفال&nbsp; </strong></p><p dir="RTL">لا ینبغي أن تستخدم ألوكار للأطفال.&nbsp;</p><p dir="RTL"><strong>تناول الأدویة الأخرى و</strong> <strong>ألوكار </strong></p><p dir="RTL">أخبر طبیبك أو الصیدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدویة أخرى .عادة لا یؤثر ألوكار على الأدویة الأخرى.</p><p dir="RTL"><strong>تناول ألوكار مع الطعام والشراب </strong>یمكن تناول ألوكار مع الطعام أو بدونھ.</p><p dir="RTL"><strong>الحمل والرضاعة الطبیعیة</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ینبغي استخدام ألوكار من قبل النساء.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تلمس أقراص ألوكار المكسورة أو المنقسمة إذا كنت امرأة حامل أو تخططین للحمل (الأقراص كاملة مغلفة لمنع ملامسة الدواء أثناء الاستخدام العادي.) وذلك لأن ھذا الدواء قد یؤثر على الأعضاء التناسلیة للطفل.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعرضت امرأة حامل لأقراص ألوكار مكسورة أو مسحوقة ، تحدث إلى طبیبك.</p><p dir="RTL"><strong>القیادة واستخدام الألات </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لیس من المحتمل أن یؤثر ألوكار على قدرتك على القیادة أو استخدام الأدوات أو الآلات.&nbsp;</p><p dir="RTL"><strong>محتوي</strong> <strong>ألوكارمن اللاكتوز </strong></p><p dir="RTL">إذا أخبرك طبیبك أنھ لا یمكنك تحمل أو ھضم بعض السكریات ، فاتصل بطبیبك قبل تناول ھذا المنتج الطبي.&nbsp;</p><p dir="RTL"><strong>محتوي</strong> <strong>ألوكار من الصودیو م </strong></p><p dir="RTL">یحتوي ھذا الدواء على أقل من ۱ ملیمول صودیوم ( ۲۳ ملجرام) لكل قرص ، وھذا یعني بشكل أساسي &quot;خالٍ من الصودیوم .&quot;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول ھذا الدواء تمامًا كما أخبرك طبیبك أو الصیدلي. استشر طبیبك أو الصیدلي إذا لم تكن متأكًدًا.&nbsp;</p><p dir="RTL"><strong>طریقة تناول ھذا الدواء </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المعتادة ھي قرص واحد كل یوم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول ھذا الدواء عن طریق الفم.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد یصف طبیبك عقار ألوكار مع دواء آخر (یسمى دوكسازوسین) للمساعدة في السیطرة على تضخم البروستاتا الحمید لدیك.</p><p dir="RTL"><strong>تناول جرعة زائدة من ألوكار أكثر مما ینبغي </strong></p><p dir="RTL">إذا تناولت عدًدًا كبیرًا جًدًا من الأقراص عن طریق الخطأ ، فاتصل بطبیبك على الفور.&nbsp;</p><p dir="RTL"><strong>إذا نسیت أن تتناول ألوكار </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسیت تناول قرص ، فتجاوز الجرعة الفائتة .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول الجرعة التالیة كالمعتاد.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مضاعفة لتعویض الجرعة المنسیة.&nbsp;</p><p dir="RTL"><strong>التوقفت عن تناول ألوكا ر </strong></p><p dir="RTL">قد تظھر حالتك تحسنًا مبكرًا بعد تناول ألوكار. ومع ذلك ، قد یستغرق الأمر ستة أشھر على الأقل حتى یتطور التأثیر الكامل. من المھم أن تستمر في تناول ألوكار طالما أخبرك طبیبك ، حتى لو لم تشعر بأي فائدة على الفور.&nbsp;</p><p dir="RTL">إذا كان لدیك أي أسئلة أخرى حول استخدام ھذا الدواء ، اسأل طبیبك أو الصیدلي.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جمیع الأدویة ، یمكن أن یسبب ھذا الدواء آثارًا جانبیة ، على الرغم من عدم حدوثھا لدى الجمیع. قد تحدث الآثار الجانبیة التال یة مع استخدام ھذا الدواء:&nbsp;</p><p dir="RTL"><strong>ردود الفعل التحسسیة </strong></p><p dir="RTL">توقف عن تناول ألوكار أقراص واتصل بالطبیب فورًا إذا واجھت أیاً من الأعراض التالیة:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجھ والشفتین واللسان أو الحلق وصعوبة البلع وصعوبة التنفس (وذمة وعائیة).&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أو حكة أو كتل تحت الجلد (الشرى) .</p><p dir="RTL"><strong>قد تشمل الآثار الجانبیة الأخرى:&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد لا تتمكن من الانتصاب (الضعف الجنسي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد یكون لدیك رغبة أقل في ممارسة الجن س.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد یكون لدیك مشاكل في القذف ، على سبیل المثال انخفاض في كمیة السائل المنوي الذي یتم إطلاقھ أثناء ممارسة الجنس. لا یبدو أن ھذا الانخفاض في كمیة السائل المنوي یؤثر على الوظیفة الجنسیة الطبیعیة.&nbsp;</p><p dir="RTL">قد تختفي ھذه الآثار الجانبیة المذكورة أعلاه بعد فترة إذا واصلت تناول ألوكار. إذا لم یكن الأمر كذلك ، فعادة ما یتم حلھا بعد التوقف ألوكار.&nbsp;</p><p dir="RTL"><strong>الآثار الجانبیة الأخرى التي تم الإبلاغ عنھا لدى بعض الرجال ھي:&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ أو إیلام الثدي .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخفقان (الشعور بضربات قلبك) .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغیرات في طریقة عمل الكبد ، والتي یمكن أن تظھر من خلال فحص الدم .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الخصیتین.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظھور دم في السائل المنوي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على الانتصاب الذي قد یستمر بعد التوقف عن تناول الدواء .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العقم عند الذكور و / أو انخفاض جودة السائل المنوي. تم الإبلاغ عن تحسن في جودة السائل المنوي بعد التوقف عن تناول الدواء .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كآبة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الدافع الجنسي الذي قد یستمر بعد التوقف عن تناول الدواء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل القذف التي قد تستمر بعد التوقف عن تناول الدواء .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلق .</p><p dir="RTL">یجب علیك إبلاغ طبیبك على الفور بأي تغییرات في أنسجة الثدي مثل ظھور الكتل ، والألم ، والتضخم أو إفرازات الحلمة لأن ھذه قد تكون علامات على حالة خطیرة ، مثل سرطان الثدي.&nbsp;</p><p dir="RTL">إذا تفاقمت أي من الآثار الجانبیة ، أو إذا لاحظت أي آثار جانبیة غیر مدرجة في ھذه النشرة ، فیرجى إخبار طبیبك أو الصیدلي. سوف یساعدك إذا قمت بتدوین ما حدث ، ومتى بدأ ، ومدة استمراره.&nbsp;</p><p dir="RTL"><strong>ما الذي یجب أن تعرفھ أیضًا عن ألوكار أقراص؟ </strong></p><p dir="RTL">غیر مرخص لاستخدام ألوكار (فیناستراید) لعلاج سرطان البروستاتا. أظھرت المعلومات التي تم جمعھا من التج ارب السریریة على الرجال الذین تناولوا فیناستراید لمدة ۷ سنوات ما یلي:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان عدد الرجال الذین أصیبوا بسرطان البروستاتا أقل لدى الرجال الذین یتناولون الفیناستراید مقارنة مع أولئك الذین لا یتناولونھ.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان عدد الرجال الذین حصلوا على درجة عالیة في نظام تصنیف الأورام أعلى لدى بعض الذین تناولوا فیناستراید مقارنةً بأولئك الذین لا یتناولونھ.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن تأثیر استخدام الفیناستراید على المدى الطویل على أورام من ھذا النوع غیر معروف.</p><p dir="RTL">إذا كنت ترغب في الحصول على مزید من المعلومات حول نظام تصنیف الورم أو ھذه التجربة ، فیرجى التحدث مع طبیبك.</p><p dir="RTL"><strong>التبلیغ عن الأعراض الجانبیة&nbsp; </strong></p><p dir="RTL">إن كان لدیك أعراض جانبیة أو لاحظ ت أعراض جانبیة غیر مذكورة في ھذه النشرة، فضلًا&nbsp; ابلغ الطبیب أوالصیدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یجب أن یحفظ في درجة حرارة أقل من ۳۰ درجة مئویة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یجب التخزین في العلبة الأصلیة للحمایة من الرطوبة.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ ھذا الدواء بعیًدًا عن رؤیة ومتناول أیدي الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم ھذا الدواء بعد تاریخ انتھاء الصلاحیة المذكور على العبوة .یشیر تاریخ انتھاء الصلاحیة إلى الیوم الأخیر من الشھر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدویة في میاه الصـرف الصـحي أو النفایات المنزلیة. اسـأل الصـیدلي عن كیفیة التخلص من الأدویة التي لم تعد تسـتخدمھا. س ـتسـاعد ھذه الإجراءات في حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما یحتویھ ألوكار أقراص&nbsp; </strong></p><p dir="RTL">المادة الفعالة&nbsp; لألوكار أقراص ھي فیناستیراید&nbsp;</p><p dir="RTL">یحتوي كل قرص مغلف على 5 ملجرام فیناستیراید المتوافق مع دستور الأدویة الأوروبي.</p><p dir="RTL"><strong>الصواغات الأخرى: </strong></p><p dir="RTL">السلیلوز دقیق التبلور ، اللاكتوز أحادي ا لھیدرات ، النشا الصودیوم جلایكولات ، دوكوسات الصودیوم ، وستیارات الماغنیسیوم.</p><p dir="RTL"><strong>الصواغات الأخرى لطبقة الكسوة الخارجیة: </strong></p><p dir="RTL">ھیبرومیلوزHPMC 2910) 6cP) و ثاني أكسید التیتانیوم وأكسید الحدید الأصفر وأكسید الحدید الأصف ر و تلك و صبغة زرقاء FD &amp; C Blue # 2 / Indigo Carmine Aluminium Lake .</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كیف یبدو ألوكار أقراص ومحتویات العبوة </strong></p><p dir="RTL">أقراص مستدیرة الشكل مطلیة باللون الأزرق ، ، منقوش علیھا حرف&quot; H&quot; على جانب واحد و&quot; ۳۷&quot; على الجانب الآخ ر <strong>كیف تتوفر: </strong></p><p dir="RTL">یتم توفیر أقراص فیناستراید ٥ ملجرام في عبوة تحتوي على شرائط .</p><p dir="RTL">تحتوي علبة ألوكار ٥ ملجرام على شرائط بھا ۳x ۱۰ أقراص.&nbsp;</p><p dir="RTL">قد لا تتوافر جمیع العبوات في السوق.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شركة أماروكس السعودیة الصناعية</strong><br />&nbsp; شارع الجامعة &ndash; الملز &ndash; الریاض 12629 المملكة العربیة السعودیة.</p><p dir="RTL">&nbsp; تلیفون: 0588 622 11 669 +<br />&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة:</strong></p><p dir="RTL">هيتيرولاب المحدودة، الوحدة الثالثة، تيلانجانا، الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة ھذه النشرة في اكتوبر ۲۰۲۳ ، نسخة ۱
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Allocar 5  (Finasteride Tablets 5mg)  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each Film Coated tablet contains Finasteride Ph.Eur 5 mg.  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Blue colour, round film coated tablets, debossed with 'H' on one side and '37' on other side.  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Allocar is indicated for the treatment and control of benign prostatic hyperplasia (BPH) in patients with an enlarged prostate to:&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cause regression of the enlarged prostate, improve urinary flow and improve the symptoms associated with BPH&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduce the incidence of acute urinary retention and the need for surgery including</p><p>transurethral resection of the prostate (TURP) and prostatectomy.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The recommended adult dose is one 5 mg tablet daily, with or without food.<strong> </strong>&nbsp;</p><p>Allocar can be administered alone or in combination with the alpha-blocker doxazosin (see section 5.1 &#39;Pharmacodynamic properties&#39;).&nbsp;</p><p>Although early improvement in symptoms may be seen, treatment for at least six months may be necessary to assess whether a beneficial response has been achieved. Thereafter, treatment should be continued long term.&nbsp;</p><p>No dosage adjustment is required in the elderly or in patients with varying degrees of renal insufficiency (creatinine clearances as low as 9 ml/min).&nbsp;</p><p>There are no data available in patients with hepatic insufficiency.&nbsp;</p><p>Allocar is contra-indicated in children.<strong> </strong>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Allocar is not indicated for use in women or children.  
 Allocar is contraindicated in the following:  
▪ Hypersensitivity to any component of this product  
▪ Pregnancy - Use in women when they are or may potentially be pregnant (see 4.6 Pregnancy and lactation, Exposure to finasteride - risk to male foetus).  

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General<strong> </strong>&nbsp;</p><p>To avoid obstructive complications it is important that patients with large residual urine and/or heavily decreased urinary flow are carefully controlled. The possibility of surgery should be an option.&nbsp;</p><p>Effects on PSA and prostate cancer detection&nbsp;</p><p>No clinical benefit has yet been demonstrated in patients with prostate cancer treated with Allocar. Patients with BPH and elevated serum prostate specific antigen (PSA) were monitored in</p><p>controlled clinical studies with serial PSAs and prostate biopsies. In these BPH studies,Allocar did not appear to alter the rate of prostate cancer detection, and the overall incidence of prostate cancer was not significantly different in patients treated with Allocar or placebo.&nbsp;</p><p>Digital rectal examination, as well as other evaluations for prostate cancer, are recommended prior to initiating therapy with Allocar and periodically thereafter. Serum PSA is also used for prostate cancer detection. Generally, a baseline PSA &gt;10 ng/mL (Hybritech) prompts further evaluation and consideration of biopsy; for PSA levels between 4 and 10 ng/mL, further evaluation is advisable. There is considerable overlap in PSA levels among men with and without prostate cancer. Therefore, in men with BPH, PSA values within the normal reference range do not rule out prostate cancer, regardless of treatment with Allocar. A baseline PSA &lt;4 ng/mL does not exclude prostate cancer.&nbsp;</p><p>Allocar causes a decrease in serum PSA concentrations by approximately 50% in patients with BPH, even in the presence of prostate cancer. This decrease in serum PSA levels in patients with BPH treated with Allocar should be considered when evaluating PSA data and does not rule out concomitant prostate cancer. This decrease is predictable over the entire range of PSA values, although it may vary in individual patients. In patients treated with Allocar for six months or more, PSA values should be doubled for comparison with normal ranges in untreated men.&nbsp;&nbsp;</p><p>This adjustment preserves the sensitivity and specificity of the PSA assay and maintains its ability to detect prostate cancer.&nbsp;</p><p>Any sustained increase in PSA levels of patients treated with finasteride 5mg should be carefully evaluated, including consideration of non-compliance to therapy with Allocar.&nbsp;&nbsp;</p><p>Drug/laboratory test interactions&nbsp;</p><p>Effect on levels of PSA&nbsp;</p><p>Serum PSA concentration is correlated with patient age and prostatic volume, and prostatic volume is correlated with patient age. When PSA laboratory determinations are evaluated, consideration should be given to the fact that PSA levels decrease in patients treated with Allocar. In most patients, a rapid decrease in PSA is seen within the first months of therapy, after which time PSA levels stabilise to a new baseline. The post-treatment baseline approximates half of the pretreatment value. Therefore, in typical patients treated with Allocar for six months or more, PSA values should be doubled for comparison to normal ranges in untreated men. For clinical interpretation, see 4.4 Special warnings and precautions for use, Effects on PSA and prostate cancer detection.&nbsp;</p><p>&nbsp;Percent free PSA (free to total PSA ratio) is not significantly decreased by Allocar. The ratio of free to total PSA remains constant even under the influence of Allocar. When percent free PSA is used as an aid in the detection of prostate cancer, no adjustment to its value is necessary.&nbsp;</p><p>Breast cancer in men&nbsp;</p><p>Breast cancer has been reported in men taking finasteride 5 mg during clinical trials and the postmarketing period. Physicians should instruct their patients to promptly report any changes in their breast tissue such as lumps, pain, gynaecomastia or nipple discharge.&nbsp;</p><p>Mood alterations and depression&nbsp;</p><p>Mood alterations including depressed mood, depression and, less frequently, suicidal ideation have been reported in patients treated with finasteride 5 mg. Patients should be monitored for psychiatric symptoms and if these occur, the patient should be advised to seek medical advice.&nbsp;</p><p>Pediatric use&nbsp;</p><p>Allocar is not indicated for use in children.&nbsp;</p><p>Safety and effectiveness in children have not been established.&nbsp;</p><p>Lactose&nbsp;</p><p>The tablet contains lactose monohydrate. Patients with any of the following genetic deficiencies should not take this medicine: problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.&nbsp;</p><p>Hepatic Insufficiency&nbsp;</p><p>The effect of hepatic insufficiency on the pharmacokinetics of finasteride has not been studied.&nbsp;</p><p>Sodium&nbsp;</p><p>This medicinal product contains less than 1 mmol (23 mg) sodium per dosage unit, that is to say essentially &#39;sodium free&#39;.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No drug interactions of clinical importance have been identified. Finasteride is metabolized primarily via, but does not appear to affect significantly, the cytochrome P450 3A4 system. Although the risk for finasteride to affect the pharmacokinetics of other drugs is estimated to be small, it is probable that inhibitors and inducers of cytochrome P450 3A4 will affect the plasma concentration of finasteride. However, based on established safety margins, any increase due to concomitant use of such inhibitors is unlikely to be of clinical significance. Compounds which have been tested in man have included propranolol, digoxin, glibenclamide, warfarin, theophylline, and phenazone and no clinically meaningful interactions were found<strong>.</strong>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy: Allocar is contra-indicated in women when they are or may potentially be pregnant (see 4.3 Contraindications).<strong> </strong>&nbsp;</p><p>Because of the ability of Type II 5 &alpha;-reductase inhibitors to inhibit conversion of testosterone to dihydrotestosterone, these drugs, including finasteride, may cause abnormalities of the external genitalia of a male foetus when administered to a pregnant woman.&nbsp;</p><p>In animal developmental studies, dose-dependent development of hypospadias were observed in the male offspring of pregnant rats given finasteride at doses ranging from 100 &mu;g/kg/day to 100 mg/kg/day, at an incidence of 3.6% to 100%. Additionally, pregnant rats produced male offspring with decreased prostatic and seminal vesicular weights, delayed preputial separation, transient nipple development and decreased anogenital distance, when given finasteride at doses below the recommended human dose. The critical period during which these effects can be induced has been defined in rats as days 16-17 of gestation.&nbsp;</p><p>The changes described above are expected pharmacological effects of Type II 5 &alpha;-reductase inhibitors. Many of the changes, such as hypospadias, observed in male rats exposed in utero to finasteride are similar to those reported in male infants with a genetic deficiency of Type II 5 &alpha;reductase. It is for these reasons that Allocar is contra-indicated in women who are or may potentially be pregnant.&nbsp;</p><p>No effects were seen in female offspring exposed in utero to any dose of finasteride.&nbsp;</p><p>Exposure to finasteride - risk to male foetus&nbsp;</p><p>Women should not handle crushed or broken tablets of Allocar when they are or may potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male foetus (see 4.6 Pregnancy and Lactation &#39;Pregnancy&#39;). Allocar tablets are coated and will prevent contact with the active ingredient during normal handling, provided that the tablets have not been broken or crushed.&nbsp;</p><p>Small amounts of finasteride have been recovered from the semen in subjects receiving finasteride 5 mg/day. It is not known whether a male foetus may be adversely affected if his mother is exposed to the semen of a patient being treated with finasteride. When the patient&#39;s sexual partner is or may potentially be pregnant, the patient is recommended to minimise exposure of his partner to semen.&nbsp;</p><p>Lactation: Allocar is not indicated for use in women.&nbsp;</p><p>It is not known whether finasteride is excreted in human milk.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;There are no data to suggest that Allocar affects the ability to drive or use machines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequent adverse reactions are impotence and decreased libido. These adverse reactions occur early in the course of therapy and resolve with continued treatment in the majority of</p><p>patients.&nbsp;</p><p>The adverse reactions reported during clinical trials and/or post-marketing use are listed in the table below.&nbsp;</p><p>Frequency of adverse reactions is determined as follows:&nbsp;</p><p>Very common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very rare (&lt;1/10,000), not known (cannot be estimated from the available data). The frequency of adverse reactions reported during post-marketing use cannot be determined as they are derived from spontaneous reports.&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:654px"><tbody><tr><td><p>System Organ Class&nbsp;</p></td><td><p>Frequency: adverse reaction&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders&nbsp;</p></td><td style="vertical-align:top"><p>Unknown: hypersensitivity reactions including swelling of the lips, tongue, throat and face&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders&nbsp;</p></td><td style="vertical-align:top"><p>Common: decreased libido&nbsp;</p><p>Unknown: decreased libido that may continue after discontinuation of therapy, depression, anxiety&nbsp;</p></td></tr><tr><td><p>Cardiac disorders&nbsp;</p></td><td><p>Unknown: palpitation&nbsp;</p></td></tr><tr><td><p>Hepatobiliary disorders&nbsp;</p></td><td><p>Unknown: increased hepatic enzymes&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders&nbsp;</p></td><td><p>Uncommon: rash&nbsp;</p><p>Unknown: pruritus, urticaria&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders&nbsp;</p></td><td style="vertical-align:top"><p>Common: impotence&nbsp;</p><p>Uncommon: ejaculation disorder, breast tenderness, breast enlargement.&nbsp;</p><p>Unknown: testicular pain, haematospermia, sexual dysfunction (erectile dysfunction and ejaculation disorder) which may continue after discontinuation of treatment; male infertility and/or poor seminal quality. Normalization or improvement of seminal quality has been reported after discontinuation of finasteride.&nbsp;</p></td></tr><tr><td><p>Investigations&nbsp;</p></td><td><p>Common: decreased volume of ejaculate&nbsp;</p></td></tr></tbody></table><p>In addition, the following has been reported in clinical trials and post-marketing use: male breast cancer (see 4.4 Special warnings and precautions for use).&nbsp;</p><p>Medical Therapy of Prostatic Symptoms (MTOPS)&nbsp;</p><p>The MTOPS study compared finasteride 5 mg/day (n=768), doxazosin 4 or 8 mg/day (n=756), combination therapy of finasteride 5 mg/day and doxazosin 4 or 8 mg/day (n=786), and placebo (n=737). In this study, the safety and tolerability profile of the combination therapy was generally consistent with the profiles of the individual components.&nbsp;</p><p>The incidence of ejaculation disorder in patients receiving combination therapy was comparable to the sum of incidences of this adverse experience for the two monotherapies.&nbsp;</p><p>Other Long-Term Data&nbsp;</p><p>In a 7 year placebo-controlled trial that enrolled 18,882 healthy men, of whom 9060 had prostate needle biopsy data&nbsp; available for analysis, prostate cancer was detected in 803 (18.4%) men receiving Allocar and 1147 (24.4%) men receiving placebo. In the Allocar group, 280 (6.4%) men had prostate cancer with Gleason scores of 7-10 detected on needle biopsy vs 237 (5.1%) men in the placebo group.</p><p>Additional analyses suggest that the increase in the prevalence of high-grade prostate cancer observed in the Allocar group may be explained by a detection bias due to the effect of Allocar on prostate volume. Of the total cases of prostate cancer diagnosed in this study, approximately 98% were classified as intracapsular (stage T1 or T2). The relationship between long-term use of Allocar and tumours with Gleason scores of 7-10 is unknown.&nbsp;</p><p>Laboratory Test Findings&nbsp;</p><p>When PSA laboratory determinations are evaluated, consideration should be given to the fact that PSA levels are decreased in patients treated with Allocar (see section 4.4 Special warnings and precautions for use). In most patients, a rapid decrease in PSA is seen within the first months of therapy, after which time PSA levels stabilise to a new baseline. The post-treatment baseline approximates half of the pre-treatment value. Therefore, in typical patients treated with Allocar for six months or more, PSA values should be doubled for comparison to normal ranges in untreated men.&nbsp;</p><p>For clinical interpretation see &#39;Special warnings and precautions for use&#39;, Effects on</p><p>prostatespecific antigen (PSA) and prostate cancer detection.&nbsp;</p><p>No other difference was observed in patients treated with placebo or Allocar in standard</p><p>laboratory tests.&nbsp;</p><p><u>Reporting of suspected adverse reactions</u>&nbsp;&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine.&nbsp;</p><p><strong><em>&bull; </em>Saudi Arabia<em>: </em></strong>&nbsp;</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:623px"><tbody><tr><td style="vertical-align:top"><p>SFDA Call Center: 19999&nbsp;</p></td></tr></tbody></table><p>&nbsp;E-mail:npc.drug@sfda.gov.sa&nbsp;<br />Website:https://ade.sfda.gov.sa/&nbsp; &nbsp;&nbsp; <strong>&nbsp;</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong></p><p><strong>Other GCC States: </strong>&nbsp;</p><p>&nbsp;Please contact the relevant competent authority.<strong> </strong>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific treatment of over dosage with Allocar is recommended. Patients have received single doses of Allocar up to 400 mg and multiple doses of Allocar up to 80 mg/day for up to three months without any adverse effects.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Finasteride is a competitive inhibitor of human 5 &alpha;-reductase, an intracellular enzyme which metabolises testosterone into the more potent androgen, dihydrotestosterone (DHT). In benign prostatic hyperplasia (BPH), enlargement of the prostate gland is dependent upon the conversion of testosterone to DHT within the prostate. Allocar is highly effective in reducing circulating and intraprostatic DHT. Finasteride has no affinity for the androgen receptor.&nbsp;</p><p>In clinical studies of patients with moderate to severe symptoms of BPH, an enlarged prostate on digital rectal examination and low residual urinary volumes, Allocar reduced the incidence of acute retention of urine from 7/100 to 3/100 over four years and the need for surgery (TURP or prostatectomy) from 10/100 to 5/100. These reductions were associated with a 2-point improvement in QUASI-AUA symptom score (range 0-34), a sustained regression in prostate volume of approximately 20% and a sustained increase in urinary flow rate.&nbsp;</p><p>Medical therapy of prostatic symptoms&nbsp;</p><p>The Medical Therapy of Prostatic Symptoms (MTOPS) Trial was a 4- to 6-year study in 3047 men with symptomatic BPH who were randomised to receive finasteride 5 mg/day, doxazosin 4 or 8 mg/day*, the combination of finasteride 5 mg/day and doxazosin 4 or 8 mg/day<!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_864" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:4.5pt;height:4.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="6" height="6" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />, or placebo. The primary endpoint was time to clinical progression of BPH,&nbsp; defined as a &ge;4 point confirmed increase from baseline in symptom score, acute urinary retention, BPH-related renal insufficiency, recurrent urinary tract infections or urosepsis, or incontinence. Compared to placebo, treatment with finasteride, doxazosin, or combination therapy resulted in a significant reduction in the risk of clinical progression of BPH by 34 (p=0.002), 39 (p&lt;0.001), and 67% (p&lt;0.001), respectively. The majority of the events (274 out of 351) that constituted BPH progression were confirmed &ge;4 point increases in symptom score; the risk of symptom score progression was reduced by 30 (95% CI 6 to 48%), 46 (95% CI 25 to 60%), and 64% (95% CI 48 to 75%) in the finasteride, doxazosin, and combination groups, respectively, compared to placebo. Acute urinary retention accounted for 41 of the 351 events of BPH progression; the risk of developing acute urinary retention was reduced by 67 (p=0.011), 31 (p=0.296), and 79% (p=0.001) in the finasteride, doxazosin, and combination groups, respectively, compared to placebo. Only the finasteride and combination therapy groups were significantly different from placebo.&nbsp;</p><p>* Titrated from 1 mg to 4 or 8 mg as tolerated over a 3-week period&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After an oral dose of 14C-finasteride in man, 39% of the dose was excreted in the urine in the form of metabolites (virtually no unchanged drug was excreted in the urine), and 57% of total dose was excreted in the faeces. Two metabolites have been identified which possess only a small fraction of the Type II 5 &alpha;-reductase activity of finasteride.&nbsp;&nbsp;</p><p>The oral bioavailability of finasteride is approximately 80%, relative to an intravenous reference dose, and is unaffected by food. Maximum plasma concentrations are reached approximately two hours after dosing and the absorption is complete within 6-8 hours. Protein binding is approximately 93%. Plasma clearance and the volume of distribution are approximately 165</p><p>ml/min and 76 l, respectively.&nbsp;</p><p>In the elderly, the elimination rate of finasteride is somewhat decreased. Half-life is prolonged from a mean half-life of approximately six hours in men aged 18-60 years to eight hours in men aged more than 70 years. This is of no clinical significance and does not warrant a reduction in dosage.&nbsp;</p><p>In patients with chronic renal impairment, whose creatinine clearance ranged from 9-55 ml/min, the disposition of a single dose of 14C-finasteride was not different from that in healthy volunteers.</p><p>Protein binding also did not differ in patients with renal impairment. A portion of the metabolites which normally is excreted renally was excreted in the faeces. It therefore appears that faecal excretion increases commensurate to the decrease in urinary excretion of metabolites. Dosage adjustment in non-dialysed patients with renal impairment is not necessary.&nbsp;</p><p>There are no data available in patients with hepatic insufficiency.&nbsp;</p><p>Finasteride has been found to cross the blood-brain barrier. Small amounts of finasteride have been recovered in the seminal fluid of treated patients.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity, genotoxicity, and carcinogenic potential. Reproduction toxicology studies in male rats have demonstrated reduced prostate and seminal vesicular weights, reduced secretion from accessory genital glands and reduced fertility index (caused by the primary pharmacological effect of finasteride). The clinical relevance of these findings is unclear.&nbsp;</p><p>As with other 5-alpha-reductase inhibitors, femininisation of male rat foetuses has been seen with administration of finasteride in the gestation period. Intravenous administration of finasteride to pregnant rhesus monkeys at doses up to 800 ng/day during the entire period of embryonic and foetal development resulted in no<strong> </strong>abnormalities in male&nbsp; foetuses. This dose is about 60-120 times higher than the estimated amount in semen of a man who have taken 5 mg finasteride, and to which a woman could be exposed via semen. In confirmation of the relevance of the Rhesus model for human foetal development, oral administration of finasteride 2 mg/kg/day (the systemic exposure (AUC) of monkeys was slightly higher (3x) than that of men who have taken 5 mg finasteride, or approximately 1-2 million times the estimated amount of finasteride in semen) to pregnant monkeys resulted in external genital abnormalities in male foetuses. No other abnormalities were observed in male foetuses and no finasteride-related abnormalities were observed in female foetuses at any dose.&rdquo;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The other ingredients are: cellulose microcrystalline, Lactose monohydrate, starch pregelatinized Sodium starch glycolate, Docusate sodium, Magnesium stearate Purified water.&nbsp;</p><p>&nbsp; Film Coating Composition: Titanium Dioxide, Yellow Iron Oxide, Hypromellose-Talc Fd&amp;C&nbsp;</p><p>Blue #2/Indigo Carmine Aluminium Lake<strong> </strong>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>3 x 10&rsquo;s Alu-Alu Blister pack<strong> </strong>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company 

Aljameah Street, Malaz quarter, 
 Riyadh 11441, Saudi Arabia 
Tel: +966 11 477 2215
Manufacture:
Hetero Lab Limited Unit III, Hyderabad, India. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>